Fig. 6From: Fargesin ameliorates osteoarthritis via macrophage reprogramming by downregulating MAPK and NF-κB pathwaysPositive feedback regulation model of macrophage activation via p38/ERK MAPK and p65/NF-κB signaling during CIOA development. Fargesin inhibits p38/ERK MAPK and p65/NF-κB activation to reprogram macrophages from M1 to M2 and mediates crosstalk between activated macrophages and apoptotic chondrocytes to prevent CIOA pathogenesis and progressionBack to article page